LITFULO Meets Both Pivotal Vitiligo Endpoints

Company Pfizer Event Type Phase 3 Topline Results (Two Pivotal Trials) Modality Oral JAK3/TEC-family kinase inhibitor Asset LITFULO (ritlecitinib) Target JAK3 and TEC-family kinases Disease Area Nonsegmental vitiligo Summary Two Phase 3 trials of oral ritlecitinib in nonsegmental vitiligo met their U.S. co-primary Week-52 endpoints…